
Pluvicto improves survival in metastatic hormone-sensitive prostate cancer across patient subgroups.
Novartis announced that Pluvicto combined with standard care significantly improves radiographic progression-free survival (rPFS) in metastatic hormone-sensitive prostate cancer (mHSPC) patients, regardless of disease volume or presentation. The PSMA...

